ATHEROSCLEROTIC LESION PHANTOM (ALP) FOR MRI/A

描述(申请人摘要逐字)：MRI技术的发展， 针对心血管疾病(CVD)应用进行了优化，目前受到阻碍 低信噪比(SNR)、组织运动和血流伪影。 这个项目的长期目标是开发一种动脉粥样硬化病变 Phantom(ALP)帮助MRI社区开发非侵入性应用程序 确定有临床急性心血管综合征风险的患者。这将是 通过以下方式完成：1)对关键病原菌的形态进行精确建模 与高危动脉粥样硬化病变相关的特征和2)提供 重现与之相关的困难的受控环境 临床影像检查。ALP将现有技术的优势与： 创新的人工动脉，包括多层壁层(AIM 1)，狭窄 形态(目标2)和MRI内容(T1、T2，对比度)相似的病变 动脉粥样硬化病变的稳定性和特征性(目标3)。在……里面 第二阶段，我们专注于优化第一阶段确定的材料和程序 期待为三期产品构建先进的流程模型 评估。一个全面的ALP将对开发和 验证新的临床应用以及培训医学 使用最先进的MRI筛查方案治疗动脉粥样硬化的人员 心血管疾病。 建议的商业应用： 临床上需要一种非侵入性手段来识别有风险的患者 斑块破裂或侵蚀如此之大，以及足够的MRI工具的商业可用性 如此有限，以至于为高度晚期的动脉粥样硬化病变创造了一个有利可图的利基市场 幻影的目标是心血管疾病。从该项目开发的产品将 满足临床研究、质量保证和人员培训方面的当前和未来需求 申请。

DESCRIPTION (Applicant's abstract verbatim): Development of MRI techniques, optimized for cardiovascular disease (CVD) applications, are currently hampered by low signal to noise ratios (SNR), tissue motion and blood flow artifacts. The long term goal of this project is to develop an Atherosclerotic Lesion Phantom (ALP) to assist the MRI community develop non invasive applications to identify patients at risk for clinically acute CV syndromes. This will be accomplished by: 1) accurately modeling the morphology of key pathogenic features associated with high risk atherosclerotic lesions and 2) providing a controlled environment that reproduces the difficulties associated with clinical imaging. ALP combines the benefits of existing technologies with: an innovative artificial artery including multiple wall layers (Aim 1), stenotic lesions that mimic the morphology (Aim 2) and MRI content (T1, T2, contrast) of atherosclerotic lesions in a stable and well characterized manner (Aim 3). In Phase II, we focus on optimizing materials and procedures identified in Phase I in anticipation of constructing advanced flow phantoms for Phase III product evaluation. A comprehensive ALP will be critical for the development and validation of new clinical applications as well as in training medical personnel on using state of the art MRI screening protocols for atherosclerotic CVD. PROPOSED COMMERCIAL APPLICATION: The magnitude of the clinical need for a non invasive means to identify patients at risk for plaque rupture or erosion is so large and the commercial availability of adequate MRI tools so limited as to create a lucrative market niche for a highly advanced atherosclerotic lesion phantom targeted at cardiovascular disease. Products developed from this project will address current and future needs in clinical research, QA, and personnel training applications.